Anti-EGFR monoclonal antibody-Tc-99

Drug Profile

Anti-EGFR monoclonal antibody-Tc-99

Alternative Names: DiaCIM; DiaCIM h-R3

Latest Information Update: 05 May 2004

Price : $50

At a glance

  • Originator CIMYM
  • Class Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 05 May 2004 Discontinued - Phase-I for Solid tumours (diagnosis) in Cuba (unspecified route)
  • 05 May 2004 Discontinued - Phase-I for Solid tumours (diagnosis) in Canada (unspecified route)
  • 28 Mar 2003 This compound is available for licensing (http://cim.sld.cu)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top